IFNA2 and neoplasm: Additionally, this study has demonstrated a significant reduction in tumor volume in an in vivo xenograft model of human melanoma with combination treatment of IFN-α-2b and ixazomib when compared to vehicle and single therapy ixazomib or IFN-α-2b.